MORF 057
Alternative Names: LY-4268989; MORF-057; MR-beta7Latest Information Update: 13 May 2025
At a glance
- Originator Harvard Medical School; Morphic Therapeutic
- Developer Eli Lilly and Company
- Class Anti-inflammatories; Small molecules
- Mechanism of Action Alpha4beta7 integrin antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Crohn's disease; Ulcerative colitis
Most Recent Events
- 09 May 2025 Eli Lilly and Company plans a phase I trial in Healthy volunteers in USA (PO) in May 2025 (NCT06964776)
- 19 Feb 2025 Morphic Therapeutic completes the phase-IIb EMERALD-1 trial for Ulcerative colitis in USA and Poland (PO, Capsule) (NCT05291689)
- 16 Aug 2024 Morphic Therapeutic has been acquired and merged into Eli Lilly and Company